Key result
This is a protocol for a Cochrane Review to quantify the blood pressure lowering efficacy of renin-angiotensin system inhibitors as second-line therapy for primary hypertension.
Why the study?
To quantify the additional reduction in SBP and DBP achieved by drugs inhibiting the renin-angiotensin system as second-line treatment for hypertensive patients.
Do drugs inhibiting the renin-angiotensin system (RAS) as second-line treatment reduce systolic and diastolic blood pressure in hypertensive patients?
Systematic Review
Do drugs inhibiting the renin-angiotensin system (RAS) as second-line treatment reduce systolic and diastolic blood pressure in hypertensive patients?
This is a protocol for a Cochrane Review to evaluate the blood pressure lowering efficacy of RAS inhibitors as second-line therapy for primary hypertension.
Answers are grounded in this paper and cite their sources.
No immediate practice change for second-line RAS inhibitors; protocol leaves open their BP-lowering efficacy in hypertension.
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective To quantify the additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) achieved by drugs inhibiting the renin‐angiotensin system (RAS) as second‐line treatment for hypertensive patients. Secondary objectives To determine the effects of second‐line RAS inhibitors on variability of blood pressure To determine the effects of second‐line RAS inhibitors on pulse pressure To quantify the effects of second‐line RAS inhibitors on heart rate To quantify the effects of second‐line RAS inhibitors on withdrawal due to adverse effects
No takes yet. Share an insight, caveat, or question.
Luo et al. (2020) conducted a systematic review in Primary hypertension. Drugs inhibiting the renin-angiotensin system (RAS) was evaluated on Additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP). This is a protocol for a Cochrane Review to quantify the blood pressure lowering efficacy of renin-angiotensin system inhibitors as second-line therapy for primary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: